anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a miscarriage preventing pill. The miscarriage preventing pill is prepared from, by weight, active pharmaceutical ingredients including 150-450 parts of radix ginseng, 120-180 parts of prepared radix astragali with honey, 120-180 parts of rhizoma atractylodis macrocephalae, 120-180 parts of parched white peony root, 120-180 parts of poria cocos, 150-450 parts of stir-baked rhizoma dioscoreae, 120-180 parts of semen nelumbinis, 120-180 parts of dried tangerine peel, 120-180 parts of roasted malt, 120-180 parts of medicated leaven, 120-180 parts of parched hawthorn fruit, 120-180 parts of radix platycodonis, 120-180 parts of agastache rugosa (Fisch. et Mey.) O. Ktze., 120-180 parts of amomum kravanh Pierre ex Gagnep., 60-140 parts of rhizoma coptidis and 120-180 parts of honey-fried licorice root as well as minor ingredients including 1344-2366 parts of honey and 576-1014 parts of beewax. The miscarriage preventing pill is capable of strengthening the spleen, benefiting qi, nourishing and harmonizing blood, removing damp, clearing heat, nourishing life, preventing miscarriage, tonifying the spleen and checking diarrhea, is safe and free from side or toxic effect and is applicable to pregnant women suffering from pregnancy vomiting and habitual abortion and having a weak constitution.
Immunodeficiency 11B with atopic dermatitis (IMD11B, OMIM:617638) is rare primary immunodeficiency disease caused by germline dominant negative (DN) mutations in the CARD11 gene. Affected patients present with immune dysfunction, recurrent infections and atopic dermatitis. In this study, we sought to identify and characterize the genetic variant in one patient with periodic fever, recurrent infections, and eczema. Trio whole-exome sequencing (WES) was employed in this patient and her parents, and Sanger sequencing validated the potential pathogenic variant. In vitro functional study was performed to evaluate the pathogenicity of genetic variant identified. A very rare missense mutation (c.2324C > T, p.S775L) in CARD11 gene (NM_032415) was identified by WES in the patient but not her parents. Luciferase reporter assays and co-immunoprecipitation demonstrated mutation exerts a dominant-interfering effect on wild-type CARD11, inhibiting the activity of NF-κB. RNA sequencing analysis also confirmed that mutant CARD11 inhibited down-stream transcriptional activity of NF-κB. A review of literature doesn't found significant genotype-phenotype correlation. We identified a vary rare DN CARD11 mutation, expanding the genetic and phenotypic spectrum of CARD11.
<P>PROBLEM TO BE SOLVED: To obtain a food composition achieving improvement of rough dry skin and increase of skin moisture.  <P>SOLUTION: This food composition contains α-linolenic acid, and a glycosphingolipid or a mucopolysaccharide. The α-linolenic acid is the one contained in Japanese basil oil, perilla oil or linseed oil. The glycosphingolipid comprises the one extracted from rice, wheat, potatoes, or the like. The mucopolysaccharide comprises hyaluronic acid, chondroitin or glucosamine, or alternatively a mixture thereof.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Duchenne muscular dystrophy (DMD) is the most common muscular disorder affecting children. It affects nearly 1 male birth over 5000. Oxidative stress is a pervasive feature in the pathogenesis of DMD. Recent work shows that the main generators of ROS are NADPH oxidases (NOX), suggesting that they are an early and promising target in DMD. In addition, skeletal muscles of mdx mice, a murine model of DMD, overexpress NOXes. We investigated the impact of diapocynin, a dimer of the NOX inhibitor apocynin, on the chronic disease phase of mdx5Cv mice. Treatment of these mice with diapocynin from 7 to 10 months of age resulted in decreased hypertrophy of several muscles, prevented force loss induced by tetanic and eccentric contractions, improved muscle and respiratory functions, decreased fibrosis of the diaphragm and positively regulated the expression of disease modifiers. These encouraging results ensure the potential role of diapocynin in future treatment strategies.
BACKGROUND: Severe community-acquired pneumonia is one of the most lethal forms of CAP with high mortality. For rapid and accurate decisions, we developed a mortality prediction model specifically tailored for elderly SCAP patients.
METHODS: The retrospective study included 2365 elderly patients. To construct and validate the nomogram, we randomly divided the patients into training and testing cohorts in a 70% versus 30% ratio. The primary outcome was in-hospital mortality. Univariate and multivariate logistic regression analyses were used in the training cohort to identify independent risk factors. The robustness of this model was assessed using the C index, ROC and AUC. DCA was employed to evaluate the predictive accuracy of the model.
RESULTS: Six factors were used as independent risk factors for in-hospital mortality to construct the prediction model, including age, the use of vasopressor, chronic renal disease, neutrophil, platelet, and BUN. The C index was 0.743 (95% CI 0.719-0.768) in the training cohort and 0.731 (95% CI 0.694-0.768) in the testing cohort. The ROC curves and AUC for the training cohort and testing cohort (AUC = 0.742 vs. 0.728) indicated a robust discrimination. And the calibration plots showed a consistency between the prediction model probabilities and observed probabilities. Then, the DCA demonstrated great clinical practicality.
CONCLUSIONS: The nomogram incorporated six risk factors, including age, the use of vasopressor, chronic renal disease, neutrophil, platelet and BUN, which had great predictive accuracy and robustness, while also demonstrating clinical practicality at ICU admission.
After sporadic reports of post-treatment control of HIV in children who initiated combination anti-retroviral therapy (cART) early, we prospectively studied 284 very-early-cART-treated children from KwaZulu-Natal, South Africa, after vertical HIV transmission to assess control of viremia. Eighty-four percent of the children achieved aviremia on cART, but aviremia persisting to 36 or more months was observed in only 32%. We observed that male infants have lower baseline plasma viral loads (P = 0.01). Unexpectedly, a subset (n = 5) of males maintained aviremia despite unscheduled complete discontinuation of cART lasting 3-10 months (n = 4) or intermittent cART adherence during 17-month loss to follow-up (n = 1). We further observed, in vertically transmitted viruses, a negative correlation between type I interferon (IFN-I) resistance and viral replication capacity (VRC) (P < 0.0001) that was markedly stronger for males than for females (r = -0.51 versus r = -0.07 for IFN-α). Although viruses transmitted to male fetuses were more IFN-I sensitive and of higher VRC than those transmitted to females in the full cohort (P < 0.0001 and P = 0.0003, respectively), the viruses transmitted to the five males maintaining cART-free aviremia had significantly lower replication capacity (P < 0.0001). These data suggest that viremic control can occur in some infants with in utero-acquired HIV infection after early cART initiation and may be associated with innate immune sex differences.
For the first 6 months, participants will meet at a community center for 3 group-based sessions and 1 individual session each month. Sessions include a 45 minute exercise component and a 45 minute dietary weight loss component. Exercise will consist of progressive aerobic and strength training. The dietary component will focus on decreasing caloric intake, while being nutritionally safe. All diets will be monitored by a Registered Dietitian. During months 7-12, participants will meet for 1 group session and 1 individual session per month. The final 12-24 months, bimonthly phone calls are provided to the participants to aid in retention efforts.
Problems such as breathlessness, exercise intolerance and loss of peripheral muscle strength can be observed in individuals who have been diagnosed with COVID19 and have been discharged. In our study, it was aimed to investigate the effect of telerehabilitation physical therapy intervention to these cases by using videoconferencing method on the physical condition of the cases. The exercise program will be a total of 6 weeks, 3 days a week. Online access will be carried out synchronously by telephone or computer, and training sessions will not be recorded in order to protect patient personal information. The cases will be evaluated online at the beginning of the study and at the end of the 6-week exercise program. The selected evaluation parameters have been selected considering the ease of online application.
Each subject will be asked to sign the Informed Consent Form (ICF). The patients diagnosed with IBS-C will be randomized in 1:1 ratio. The treatment will be administrated according to the approved leaflet and study procedures. Eligible patients will be randomized to receive either GA-AT0119 or Placebo. Patients will be treated according to the approved leaflet. The study subjects will return at day 7, 15 and day 28 for evaluation. Each subject will undergo a washout period of 28 days. At Day 56 each subject will be evaluated and will receive the crossover therapy line and start administration. Subject will be evaluated at Day 84 at the end of the crossover period. Patients will be evaluated for constipation symptoms, global assessment for tolerability, safety. Each subject will receive a diary where bowel frequency, type and transit time will be completed during product administration. From visit 2 to visit 6, patients will be evaluated for treatment adherence and clinical symptoms recurrences. Each subject will complete 2 additional phone follow-ups Visit for safety reporting and clinical symptoms recurrences according to protocol. During the follow-up visits subject will be evaluated also by using Likert scale for Abdominal Pain and discomfort, Sickness Impact Profile score, IBS-VAS scale and IBS-QoL.
In the current study the investigators aim to assess the effects of low intensity focused ultrasound (LIFUS) on the symptoms of primary orthostatic tremor (POT) and on brain connectivity. LIFUS is a promising non-invasive brain stimulation technique that is actively being studied for its ability to reversibly modulate brain activity. By focusing the propagation of acoustic wave through the skull, a higher degree of spatial specificity and deep targeting can be achieved over other non-invasive stimulation methods such as transcranial magnetic stimulation (TMS) and transcranial direct-current stimulation (tDCS). Specifically, investigators will use LIFUS to stimulate the cerebellum bilaterally for 80s per hemisphere using a theta burst protocol that investigators have shown to induce plasticity. Investigators hypothesize that modulating cerebellar activity will decrease symptoms of POT and normalize the dysfunctional cerebello-thalamo-cortico network. 15 POT patients will be recruited to participate in 3 sessions in-lab. The first visit will involve an anatomical magnetic resonance image (MRI) scan. This will allow us to accurately target cerebellar lobule VIII and establish the appropriate parameters of LIFUS to effectively pass through the skull. In visits 2 and 3 participants will be seated in a comfortable chair and an anatomical MRI image will be used to position the LIFUS transducer over cerebellar lobule VIII bilaterally on surface of their head. In visit 2, clinical assessments of POT will be conducted through electromyography (EMG) recordings and video analysis of posture and sway. Symptoms prior to and after LIFUS will be compared. Investigators will compare the effects of real stimulation to a sham stimulation. In visit 3, Investigators will assess brain network activity using transcranial magnetic stimulation (TMS) by employing an established paired-pulse paradigm. This method will allow us to establish the effects of LIFUS on the cerebello-thalamo-cortical network and determine how this related to changes observed in POT symptoms.
S. pneumoniae whole cell vaccine (SPWCV) is a vaccine candidate made from whole unencapsulated pneumococcal cells and adsorbed to aluminum hydroxide adjuvant (Alum). After adsorption of the Alum to SPWCV, the vaccine is referred to as PATH-wSP. PATH-wSP has been previously tested in Phase 1/2 studies in healthy US adults (VAC-002), and in healthy Kenyan adults and toddlers (VAC-010) and showed a favorable safety, tolerability, and immunogenicity profile. The SPWCV and Alum used in previous Phase 1/2 trials were supplied separately in a two-vial configuration; the SPWCV was manufactured at Walter Reed Army Institute of Research and the Alum at Instituto Butantan. A single-vial formulation of PATH wSP, an adsorbed suspension of SPWCV and Alum, has now been manufactured by PT Bio Farma, Indonesia. The purpose of this study was to assess the safety and tolerability of this new formulation.
Naive volunteers tested with 30 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
The invention relates to a device for safety-relevant applications. The device has a user interface. The user interface is designed to display digital bits. The digital bits are set to a digital value assigned by the user. The user interface is designed to limit the selection of digital bits available for user input when a digital value is input by the user on one of the digital bits to be assigned (e.g. his/her first input). The invention also relates to a method for a user to operate a device for security-related purposes.
<P>PROBLEM TO BE SOLVED: To provide a body care product having high persistence of cooling effects and high persistence of a sound produced when foam of a foamed aerosol stock solution is broken and affording massage effects with skin touch for the foam breaking over a relatively long period.  <P>SOLUTION: The body care product is provided with an aerosol container in which the aerosol stock solution and a liquefied gas as a propellent are sealed and a flexible sheet body having a surface to be coated which can be coated with the aerosol stock solution jetted from the aerosol container and the coated surface can be applied to a human body. The aerosol stock solution is prepared by formulating 0.05-10 wt.% of a water-soluble polymer, 0.1-10 wt.% of a surfactant and 0.5-20 wt.% of an oil. Furthermore, 10 pts.wt. of the aerosol stock solution and 10-90 pts.wt. of the liquefied gas are sealed in the aerosol container. The sheet-like body made of fibers and having a prescribed water absorption percentage is arranged on the surface to be coated with the aerosol of the flexible sheet body and the surface to be coated is coated with the aerosol and applied to the human body.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The present invention relates to A-decarbon-5 alpha-androstane-2-ketone-17 beta-alcohol ester with PPARalpha/beta/gamma triple excitant activity. The structural formula is also disclosed. The preparation method of the steride comprises an esterification reaction between substituted phenoxy acetyl chloride or substituted nicotinic acid chloride and 17 beta-hydroxy-A-decarbon-5 alpha-androstane-2-ketone in pyridinium solvent in the presence of 4-dimethylamino pyridine as a catalyst; the reaction temperature is-7 DEG C to 10 DEG C, and the reaction time is 15 minutes to 12 hours; a steride with PPARalpha/beta/gamma triple excitant activity is obtained. The constant of each component in the reaction is 1.5 mol of substituted phenoxy acetyl chloride or 1 to 2 mol of substituted nicotinic acid chloride and 1 mol of 17 beta-hydroxy-A-decarbon-5 alpha-androstane-2-ketone. The method of the present invention has the characteristics of simple operation, good yield, high purity of product, etc. The steride prepared by using the method of the present invention is used as a medicine for treating type II diabetes in clinic.
Epilepsy is a brain disorder affecting up to 1 in 26 individuals. Despite its clinical importance, the molecular mechanisms of epileptogenesis are still far from clarified. Our previous study showed that disruption of Clock in excitatory neurons alters cortical circuits and leads to generation of focal epilepsy. In this study, a GAD-Cre;Clockflox/flox mouse line with conditional Clock gene knockout in inhibitory neurons was established. We observed that seizure latency was prolonged, the severity and mortality of pilocarpine-induced seizure were significantly reduced, and memory was improved in GAD-Cre;Clockflox/flox mice. We hypothesize that mice with CLOCK knockout in inhibitory neurons have increased threshold for seizure, opposite from mice with CLOCK knockout in excitatory neurons. Further investigation showed Clock knockout in inhibitory neurons upregulated the basal protein level of ARC, a synaptic plasticity-associated immediate-early gene product, likely through the BDNF-ERK pathway. Altered basal levels of ARC may play an important role in epileptogenesis after Clock deletion in inhibitory neurons. Although sEPSCs and intrinsic properties of layer 5 pyramidal neurons in the somatosensory cortex exhibit no changes, the spine density increased in apical dendrite of pyramidal neurons in CLOCK knockout group. Our results suggest an underlying mechanism by which the circadian protein CLOCK in inhibitory neurons participates in neuronal activity and regulates the predisposition to epilepsy.
PURPOSE:To provide the tape agent and tape prepn. which hardly generate moistening, a rash, itching, etc., by sweating from the skin surface in spite of patching on the skin surface over a long time and produces decreased stimulus on the skin surface. CONSTITUTION:A tacky adhesive layer is formed on at least one surface of a porous supporting base having 40 to 98% pore volume regulated in JIS (Japanese Industrial Standards) L-1096. A porous supporting base having <=100mm stiffness and softness (45 deg. cantilever method) is preferably adopted for the layer in terms of flexibility, the flow-up characteristic to the skin and the stimulativeness to the skin. The tape prepn. for treatment and prevention of diseases is obtd. by incorporating a drug for percutaneous absorption into the tacky adhesive layer.
Aphthous stomatitis affecting the mucous membranes of the mouth, lips, cheeks and gums is treated by topical applicn. of a tape dosage contg. a minor amt. of a topically effective antiviral, antibiotic, antibacterial, antimicrobial or antiinfective agent (I) which is localised on the tape at either (a) the central portion of the tape, the adhesive surfaces of which form an adhesive border around (I) or (b) the adhesive layer of tape. Pref. (I) is present in amt. 1-15 (esp. 1-5) mg, and the tape has surface area 9-625 sq.mm. Pref. the tape isolates (I) from the areas adjacent to its applicn., and the tape is a buccal tape. The method can also be used to treat Herpes Simplex labialis and the sores, lesions and blisters it causes.
PURPOSE:To provide a troche not having a rough touch or a powdery touch, having a slimy touch and readily administered by containing xylitol and gelatin. CONSTITUTION:Xylitol as an excipient, gelatin as a binder, further medicinal ingredients such as an antiseptic, sterilizing agent, antibiotic, local analgesic, antitussive, expectorant, astringent or tooth cleanser and if necessary a lubricant, a flavor, etc., usually used for troches are compounded with each other and molded by a wet molding method, a compression molding method, etc., to provide the objective troche. The gelatin is compounded in an amount of 0.1-2.0 pts. wt., preferably 0.2-8 pts. wt., per 100 pts. wt. of the xylitol. The xylitol is used in an amount of 25-99%, preferably 50-99%, of the whole weight of the troche.
PURPOSE:To produce easily a solid silicone oil which is easily soluble in water, has improved dispersibility, immediate effects and simply handleable, by blending a sukucibe oil with a solid surface active agent and water at a temperature >=a softening point of the surface active agent, solidifying the blend. CONSTITUTION:(A) 5-50pts.wt. silicone oil such as dimethyl silicone, or methylphenyl silicone is blended with (B) 10-70pts.wt. solid surface active agent selected from a group consisting of a quaternary alkylammonium salt (e.g., distearlydimethylammonium salt), a nonionic surface active agent (e.g., polyoxyethylene alkykl phenyl ether) and fatty acid soap (e.g., 12-18C alkali metal salt), and 10-70pts.wt. water, and <=40pts.wt. silicon oxide, etc. as an arbitrary component at a temperature >=the softening point of the component B, allowed to stand or cooled, and solidified.
The present invention generally relates to a method for an improved treatment for Alzheimer~s disease (AD) using immunotherapy, e.g., immunotherapy targeting .beta. amyloid (A.beta.), e.g. immunotherapy based on AN1792. In one embodiment, the method allows for predicting an adverse clinical response, and therefore allows for an improved safety profile of AN1792. In another embodiment, the method allows for predicting a favorable clinical response, and therefore allows for an improved efficacy profile of AN1792. The methods of the present invention may be combined to predict a favorable clinical response and the lack of an adverse clinical response.
Participants in this group will take part in an 8-week supervised exercise program at the YMCA. Following the 8-week intervention, participants will have the option to continue for an additional 8-weeks at the YMCA (fee for service) or follow an 8-week self-directed program.
Inflammasome activation is implicated in diseases of aberrant angiogenesis such as age-related macular degeneration (AMD), though its precise role in choroidal neovascularization (CNV), a characteristic pathology of advanced AMD, is ill-defined. Reports on inhibition of inflammasome constituents on CNV are variable and the precise role of inflammasome in mediating pathological angiogenesis is unclear. Historically, subretinal injection of inflammasome agonists alone has been used to investigate retinal pigmented epithelium (RPE) degeneration, while the laser photocoagulation model has been used to study pathological angiogenesis in a model of CNV. Here, we report that the simultaneous introduction of any of several disease-relevant inflammasome agonists (Alu or B2 RNA, Alu cDNA, or oligomerized amyloid β (1-40)) exacerbates laser-induced CNV. These activities were diminished or abrogated by genetic or pharmacological targeting of inflammasome signaling constituents including P2rx7, Nlrp3, caspase-1, caspase-11, and Myd88, as well as in myeloid-specific caspase-1 knockout mice. Alu RNA treatment induced inflammasome activation in macrophages within the CNV lesion, and increased accumulation of macrophages in an inflammasome-dependent manner. Finally, IL-1β neutralization prevented inflammasome agonist-induced chemotaxis, macrophage trafficking, and angiogenesis. Collectively, these observations support a model wherein inflammasome stimulation promotes and exacerbates CNV and may be a therapeutic target for diseases of angiogenesis such as neovascular AMD.
Patients are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7+3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received will depend on response.